Classical Hodgkin lymphoma is one of the more frequent lymphomas and is generally
considered a highly curable disease with standard first-line chemotherapy and radiotherapy …

Hodgkin lymphoma (HL) is a B cell lymphoma characterized by few malignant cells and
numerous immune effector cells in the tumour microenvironment. The incidence of HL is …

Background Five-year follow-up in a trial involving patients with previously untreated stage
III or IV classic Hodgkin's lymphoma showed long-term progression-free survival benefits …

Background Combined-modality treatment consisting of chemotherapy and consolidation
radiotherapy is standard of care for patients with early-stage unfavourable Hodgkin …

Background Despite advances in the treatment of Hodgkin lymphoma with the introduction
of PET-adapted regimens, practical challenges prevent more widespread use of these …

The scarcity of malignant Hodgkin and Reed–Sternberg cells hampers tissue-based
comprehensive genomic profiling of classic Hodgkin lymphoma (cHL). By contrast, liquid …

Hodgkin lymphoma (HL) is an uncommon malignancy of B-cell origin. Classical HL (cHL)
and nodular lymphocyte–predominant HL are the 2 main types of HL. The cure rates for HL …

The NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma (HL) provide
recommendations for the management of adult patients with HL. The NCCN panel meets at …

Tumor-positive resection margins after surgery can result in tumor recurrence and
metastasis. Although adjuvant postoperative radiotherapy and chemotherapy have been …

Hodgkin lymphoma (HL) is a rare malignancy accounting for roughly 15% of all lymphomas
and mostly affecting young patients. A second peak is seen in patients above 60 years of …